EBV peptide–MHC complex (from EBNA1, LMP1, or LMP2A)

EBV peptide–MHC complexes from EBNA1, LMP1, and LMP2A are immunologically relevant complexes formed by the binding of peptides derived from EBV latent proteins to host MHC class I or II molecules. These complexes are recognized by cytotoxic T lymphocytes and serve as key targets for immune control and immunotherapy of EBV infection and associated cancers. EBNA1-derived peptides are major targets for CTL but exhibit immune evasion features, such as inhibition of their own antigen presentation through glycine-alanine repeats. LMP1 and LMP2A peptides modulate multiple aspects of the immune response and cell survival, contributing to both pathogen persistence and oncogenesis. Therapies targeting these complexes are being developed, including adoptive T cell transfer and TCR-like antibodies. However, immune evasion by EBV, presentation heterogeneity, and safety challenges remain significant barriers.

Other names

EBV antigen-MHC complexEBV peptide-MHC class I complexEBNA1/LMP1/LMP2A epitope–MHC complex

Recognition and killing of infected or malignant cells displaying these complexes by cytotoxic T lymphocytes Induction of antibody-dependent or complement-dependent cytotoxicity by TCR-like antibodies